Trial Profile

Second phase 1 study of IkT-148009 in newly diagnosed and early stage Parkinson's patients

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 15 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Risvodetinib (Primary)
Indications Parkinson's disease
Focus Adverse reactions; First in man; Pharmacodynamics

Most Recent Events

15 Mar 2019 New trial record
26 Feb 2019 According to an Inhibikase Therapeutics media release, this trial is expected to begin in 2Q 2019.
26 Feb 2019 According to an Inhibikase Therapeutics media release, company has filled IND with the U.S. Food and Drug Administration (FDA) to initiate this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com